A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X
Source abstract
Abstract
We previously developed a hexon-specific PEGylated adenovirus (Ad) vector by utilizing avidin-biotin interaction. However, the Ad vector was aggregated due to the multiple interactions between avidin and biotin, resulting in a reduction in the transduction efficiencies in the organs following systemic administration. In this study, we developed a new method for hexon-specific PEGylation by mixing Ad vectors with PEGylated blood coagulation factor X (FX) (PEG-FX). FX specifically binds to the hexon protein, suggesting that FX serves as an adaptor molecule for hexon-specific modification. Intravenous administration of the PEG-FX-associated Ad (PEG-FX-Ad) vector into conventional mice resulted in prolonged blood retention. However, the transduction efficiencies in the liver were not reduced by PEG-FX. On the other hand, in the warfarinized mice, the PEG-FX-Ad vectors exhibited a significant reduction in the liver transduction. In addition, incubation of the PEG-FX-Ad vector with unmodified FX resulted in dissociation of PEG-FX from the Ad vector, indicating that a substitution of PEG-FX with endogenous FX occurs in the blood following administration. This study demonstrates that FX can be used as an adaptor molecule for hexon-specific modification; however, modified FX might be substituted with endogenous FX in the blood.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · Viral Infectious Diseases and Gene Expression in Insects · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Retargeting adenoviral vectors to improve gene transfer into tumors10.1038/cgt.2010.78 ↗
2. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX10.1128/JVI.02665-09 ↗
3. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma10.1038/cgt.2010.40 ↗
4. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]10.1038/mt.2009.80 ↗
5. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver10.1038/mt.2008.307 ↗
6. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector10.1016/S1525-0016(03)00243-0 ↗
7. Blood clearance rates of adenovirus type 5 in mice10.1099/0022-1317-81-11-2605 ↗
8. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo10.1089/10430349950018021 ↗
9. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver10.1089/104303402760372972 ↗
10. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro10.1038/sj.gt.3300665 ↗
11. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability10.1002/jgm.699 ↗
12. Stable stealth function for hollow polyelectrolyte microcapsules through a poly(ethylene glycol) grafted polyelectrolyte adlayer10.1021/bm700857s ↗
13. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration10.1016/j.jconrel.2007.06.010 ↗
14. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy10.1016/j.addr.2010.05.001 ↗
15. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies10.1038/sj.mt.6300306 ↗
16. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses10.1016/j.ymthe.2004.09.015 ↗
17. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide10.1038/sj.mt.6300321 ↗
18. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction10.1016/j.biomaterials.2010.10.060 ↗
19. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo10.1073/pnas.0711757105 ↗
20. Adenovirus serotype 5 hexon mediates liver gene transfer10.1016/j.cell.2008.01.016 ↗
21. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob10.1038/sj.gt.3301453 ↗
22. The structure of the adenovirus capsid. III. Hexon packing determined from electron micrographs of capsid fragments10.1016/0022-2836(87)90459-1 ↗
23. Characterization of a permissive epitope insertion site in adenovirus hexon10.1128/JVI.00256-06 ↗
24. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob10.1016/j.virusres.2010.08.021 ↗
25. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes10.1182/blood-2006-04-008532 ↗
26. Influence of coagulation factor × on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors10.1038/mt.2009.152 ↗
27. The effect of heat on the anatomy of the adenovirus10.1099/0022-1317-1-4-509 ↗
28. Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes10.1126/stke.3452006pl4 ↗
29. Detection of phosphorylated T and B cell antigen receptor species by Phos-tag SDS- and Blue Native-PAGE10.1016/j.imlet.2009.12.012 ↗
30. Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells10.1186/1743-422X-7-148 ↗
31. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation10.1128/JVI.77.24.13062-13072.2003 ↗
32. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity10.1038/nbt812 ↗
33. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor10.1111/j.1742-4658.2009.07387.x ↗
34. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin10.1021/bc050355d ↗
35. Protein structural requirements for Ca2+ binding to the light chain of factor X. Studies using isolated intact fragments containing the gamma-carboxyglutamic acid region and/or the epidermal growth factor-like domains10.1016/S0021-9258(18)52264-X ↗
36. Structure and dynamics of zymogen human blood coagulation factor X10.1016/S0006-3495(02)75476-3 ↗
37. Targeting adenoviruses with factor x-single-chain antibody fusion proteins10.1089/hum.2009.190 ↗
38. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus10.1089/hum.2009.028 ↗
39. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis10.1038/gt.2009.95 ↗
40. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation10.1038/sj.gt.3302945 ↗
41. Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer10.1038/mt.2011.71 ↗
42. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells10.1038/mt.2010.229 ↗